Try our beta test site
301 studies found for:    nivolumab | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Nivolumab in Symptomatic Brain Metastases
Conditions: Melanoma;   Brain Metastasis
Intervention: Drug: Nivolumab
2 Recruiting Neoadjuvant Nivolumab in Glioblastoma
Condition: Glioblastoma Multiforme
Intervention: Drug: Nivolumab
3 Not yet recruiting Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers
Conditions: Refractory or Recurrent Hypermutated Malignancies;   Biallelic Mismatch Repair Deficiency (bMMRD) Positive Patients
Intervention: Drug: Nivolumab
4 Not yet recruiting Study of Concurrent Intravenous and Intrathecal Nivolumab for Patients With Leptomeningeal Disease (LMD)
Conditions: Melanoma and Other Malignant Neoplasms of Skin;   Leptomeningeal Disease
Intervention: Drug: Nivolumab
5 Recruiting A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)
Condition: Renal Cell Carcinoma
Intervention: Drug: nivolumab
6 Not yet recruiting Neoadjuvant Nivolumab With and Without Urelumab in Patients With Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder
Conditions: Urothelial Carcinoma;   Bladder Cancer
Interventions: Drug: Nivolumab in combination with Urelumab;   Drug: Nivolumab monotherapy
7 Recruiting Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer
Conditions: Advanced Non-small Cell Lung Cancer;   Metastatic Non-small Cell Lung Cancer;   Lung Neoplasms
Interventions: Biological: Vigil™;   Drug: Nivolumab
8 Recruiting Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma
Conditions: Carcinoma, Renal Cell;   Clear-cell Metastatic Renal Cell Carcinoma
Intervention: Biological: Nivolumab/Ipilimumab
9 Not yet recruiting Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies
Condition: Hematologic Malignancies
Intervention: Drug: Nivolumab
10 Recruiting Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
Conditions: Biliary Tract Cancer;   Biliary Tract Neoplasms
Intervention: Drug: Nivolumab
11 Not yet recruiting Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer
Condition: Oral Cavity SCC
Intervention: Drug: Nivolumab
12 Recruiting Nivolumab With DC Vaccines for Recurrent Brain Tumors
Conditions: Malignant Glioma;   Astrocytoma;   Glioblastoma
Interventions: Drug: nivolumab;   Biological: DC
13 Not yet recruiting BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer
Conditions: Carcinoma, Non-Small-Cell Lung;   Carcinoma, Small Cell Lung
Intervention: Drug: Nivolumab, Ipilimumab
14 Recruiting Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
Conditions: Melanoma;   Renal Cell Carcinoma;   Non-Small Cell Lung Cancer
Intervention: Drug: HBI-8000 in combination with nivolumab
15 Not yet recruiting MGCD516 Combined With Nivolumab in Renal Cell Cancer (RCC)
Conditions: Malignant Neoplasms of Urinary Tract;   Other Disorders of Kidney and Ureter;   Renal Cell Carcinoma
Interventions: Drug: MGCD516;   Drug: Nivolumab
16 Recruiting A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors
Conditions: Carcinoma,Non-Small-Cell Lung;   Carcinoma, Renal Cell;   Melanoma
Intervention: Drug: Combination of NKTR-214 + nivolumab
17 Recruiting Nivolumab in Acute Myeloid Leukemia (AML) in Remission at High Risk for Relapse
Conditions: Leukemia;   Acute Myeloid Leukemia
Intervention: Drug: Nivolumab
18 Not yet recruiting A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers
Conditions: Gastrointestinal Cancer;   Neuroendocrine Tumours;   Malignant Female Reproductive System Neoplasm
Interventions: Drug: Ipilimumab;   Drug: Nivolumab
19 Not yet recruiting Trial of Measles Virotherapy in Combination With Nivolumab in Patients With Metastatic Non-Small Cell Lung Cancer
Condition: Recurrent Non-Small Cell Lung Cancer
Interventions: Biological: MV-NIS;   Biological: Nivolumab
20 Recruiting A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases
Conditions: Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Drug: nivolumab;   Drug: ipilimumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.